CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 180 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2021. The put-call ratio across all filers is 0.46 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $51,545 | -65.2% | 1,873 | -57.1% | 0.00% | -60.0% |
| Q2 2023 | $148,240 | +189951.3% | 4,369 | +100.6% | 0.01% | +150.0% |
| Q1 2023 | $78 | +500.0% | 2,178 | +604.9% | 0.00% | +100.0% |
| Q4 2022 | $13 | -100.0% | 309 | -95.5% | 0.00% | -66.7% |
| Q3 2022 | $192,000 | -37.5% | 6,805 | -40.2% | 0.00% | -57.1% |
| Q2 2022 | $307,000 | +176.6% | 11,386 | +249.2% | 0.01% | +600.0% |
| Q1 2022 | $111,000 | -19.6% | 3,261 | -8.9% | 0.00% | -50.0% |
| Q4 2021 | $138,000 | -78.9% | 3,580 | -70.4% | 0.00% | -88.2% |
| Q3 2021 | $654,000 | +1353.3% | 12,105 | +798.7% | 0.02% | +1600.0% |
| Q2 2021 | $45,000 | -63.7% | 1,347 | -80.9% | 0.00% | -75.0% |
| Q4 2020 | $124,000 | +1450.0% | 7,052 | +45.6% | 0.00% | – |
| Q1 2020 | $8,000 | -27.3% | 4,843 | +1.1% | 0.00% | -100.0% |
| Q4 2019 | $11,000 | +120.0% | 4,789 | +92.6% | 0.00% | – |
| Q3 2019 | $5,000 | -44.4% | 2,486 | +43.8% | 0.00% | -100.0% |
| Q1 2019 | $9,000 | – | 1,729 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
| Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
| TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
| 5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
| COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
| ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
| Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
| RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
| Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
| Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |